Furthermore, there are still other clinically relevant biomarkers including prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), prostate secretory protein-94 (PSP94), and circulating tumor cells. Here, FOLH1 is linked to neoplasm.